← Leaderboards
Paulo Cesar Rodriguez
H. Lee Moffitt Cancer Ctr & Res Inst
$11,501,509
Attributed
$11,501,509
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2006–25$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,501,509 · 14
By mechanism
R01$7,755,490 · 4
P01$1,636,127 · 2
P30$996,741 · 3
P20$782,681 · 4
R21$330,470 · 1
Top collaborators
No co-investigators on record.
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Conor C Lynch$9,082,731
- Brooke L Fridley$4,952,468
- Natarajan Raghunand$3,068,009
- John M Koomen$3,679,194
- Brian D Gonzalez$3,512,699
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorT-LymphocyteCellsCell PhysiologyLinkPathway InteractionsSignal TransductionImmuneTumor ImmunityT Cell ResponseNovel Therapeutic InterventionProteinsImmunotherapyImmunityInsightResponseMyeloid-Derived Suppressor CellsBaseMyeloid CellsCancer ImmunotherapyIn VivoMyelogenousFoundations
Grant awards (43)
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors$770,888
R01 · FY2025 · CA · contact PI
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds$376,751
R01 · FY2025 · CA · contact PI
Project 4$318,724
P01 · FY2025 · CA · contact PI
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors$366,172
R01 · FY2024 · CA · contact PI
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds$357,915
R01 · FY2024 · CA · contact PI
Project 4$314,539
P01 · FY2024 · CA · contact PI
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands$385,581
R01 · FY2023 · CA · contact PI
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors$377,735
R01 · FY2023 · CA · contact PI
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds$369,216
R01 · FY2023 · CA · contact PI
Project 4$327,992
P01 · FY2023 · CA · contact PI
Flow Cytometry Core$1
P30 · FY2023 · CA · contact PI
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands$385,581
R01 · FY2022 · CA · contact PI
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors$385,444
R01 · FY2022 · CA · contact PI
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds$369,216
R01 · FY2022 · CA · contact PI
Project 4$333,121
P01 · FY2022 · CA · contact PI
Plant-derived extracts regulate immunosuppressive myelopoiesis in Breast cancer patients$210,625
R01 · FY2022 · CA · contact PI
Flow Cytometry Core$162,193
P30 · FY2022 · CA · contact PI
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands$393,450
R01 · FY2021 · CA · contact PI
Bile acids restrict functional reprogramming of myeloid-derived suppressor cells in tumor beds$376,751
R01 · FY2021 · CA · contact PI
Project 4$341,751
P01 · FY2021 · CA · contact PI
Flow Cytometry Core$71,004
P30 · FY2021 · CA · contact PI
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands$393,450
R01 · FY2020 · CA · contact PI
Flow Cytometry Core$71,002
P30 · FY2020 · CA · contact PI
Flow Cytometry Core$4,498
P30 · FY2020 · CA · contact PI
Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands$393,450
R01 · FY2019 · CA · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$381,646
R01 · FY2019 · CA · contact PI
Cellular Immunology and Immune Metabolism Core$100,096
P30 · FY2019 · GM · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$393,450
R01 · FY2018 · CA · contact PI
Cellular Immunology and Immune Metabolism Core$128,733
P30 · FY2018 · GM · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$237,882
R01 · FY2017 · CA · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$137,679
R01 · FY2017 · CA · contact PI
Cellular Immunology and Immune Metabolism Core$131,942
P30 · FY2017 · GM · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$343,658
R01 · FY2016 · CA · contact PI
Cellular Immunology and Immune Metabolism Core$161,718
P30 · FY2016 · GM · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$252,705
R01 · FY2015 · CA · contact PI
Cellular Immunology and Immune Metabolism Core$165,554
P30 · FY2015 · GM · contact PI
Stress Pathways in Tumors Drive Global MDSC Activity and Survival through Chop$96,245
R01 · FY2015 · CA · contact PI
Notch-1 in T Cells: a central mediator of tumor induced anergy$145,160
R21 · FY2013 · CA · contact PI
Notch-1 in T Cells: a central mediator of tumor induced anergy$185,310
R21 · FY2012 · CA · contact PI
L-ARGININE AVAILABILITY REGULATES PROLIFERATION OF MALIGNANT T-CELLS$192,757
P20 · FY2011 · RR · contact PI
L-ARGININE AVAILABILITY REGULATES PROLIFERATION OF MALIGNANT T-CELLS$172,755
P20 · FY2010 · RR · contact PI
L-ARGININE AVAILABILITY REGULATES PROLIFERATION OF MALIGNANT T-CELLS$198,775
P20 · FY2009 · RR · contact PI
LSUHSC COBRE: CORE 1: IMMUNOLOGY & CELL ANALYSIS$218,394
P20 · FY2006 · RR · contact PI